Oculis reported that its Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema missed the primary vision endpoint, so it will not pursue an FDA filing for that program. The drug did show meaningful retinal thickness reduction and was well tolerated, and the company said it will shift focus to its Privosegtor and Licaminlimab late-stage programs while relying on a strong cash position of about $278 million into 2H 2029.

What happened

The key miss was that OCS-01 did not improve best corrected visual acuity at week 52 in either DIAMOND-1 or DIAMOND-2. The secondary retinal thickness endpoint was positive, but that was not enough to support a regulatory path in DME. The company said it will stop pursuing FDA filing for OCS-01 in this indication.

Why it matters

This is a classic “biology moved, clinical win didn’t” outcome. The data suggest the eye drop affected anatomy, but not enough to deliver the vision improvement the market needed. That usually pushes investors to focus on the next pipeline assets rather than the failed lead.

Company read-through

Management is trying to keep the story centered on the rest of the pipeline, especially Privosegtor in optic neuropathies and Licaminlimab in dry eye disease. The cash balance is still strong, so the failure does not create an immediate financing problem. The market reaction will likely depend on whether investors believe the remaining programs can carry the company forward.

One-line takeaway

OCS-01 missed the commercial/regulatory bar in DME, but Oculis still has cash and two other late-stage shots on goal.